Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6UY3

Structure of anti-hCD33 conditional scFv with methotrexate

Summary for 6UY3
Entry DOI10.2210/pdb6uy3/pdb
Related3F12 6uup
DescriptorAnti-CD33 conditional scFv, PHOSPHATE ION, GLYCEROL, ... (5 entities in total)
Functional Keywordsconditional car, mtx, cd33, conditional antibody, antitumor protein
Biological sourceCamelidae mixed library
Total number of polymer chains1
Total formula weight29364.86
Authors
Kimberlin, C.R.,Park, S. (deposition date: 2019-11-11, release date: 2020-11-18, Last modification date: 2024-11-13)
Primary citationPark, S.,Pascua, E.,Lindquist, K.C.,Kimberlin, C.,Deng, X.,Mak, Y.S.L.,Melton, Z.,Johnson, T.O.,Lin, R.,Boldajipour, B.,Abraham, R.T.,Pons, J.,Sasu, B.J.,Van Blarcom, T.J.,Chaparro-Riggers, J.
Direct control of CAR T cells through small molecule-regulated antibodies.
Nat Commun, 12:710-710, 2021
Cited by
PubMed Abstract: Antibody-based therapeutics have experienced a rapid growth in recent years and are now utilized in various modalities spanning from conventional antibodies, antibody-drug conjugates, bispecific antibodies to chimeric antigen receptor (CAR) T cells. Many next generation antibody therapeutics achieve enhanced potency but often increase the risk of adverse events. Antibody scaffolds capable of exhibiting inducible affinities could reduce the risk of adverse events by enabling a transient suspension of antibody activity. To demonstrate this, we develop conditionally activated, single-module CARs, in which tumor antigen recognition is directly modulated by an FDA-approved small molecule drug. The resulting CAR T cells demonstrate specific cytotoxicity of tumor cells comparable to that of traditional CARs, but the cytotoxicity is reversibly attenuated by the addition of the small molecule. The exogenous control of conditional CAR T cell activity allows continual modulation of therapeutic activity to improve the safety profile of CAR T cells across all disease indications.
PubMed: 33514714
DOI: 10.1038/s41467-020-20671-6
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon